Nippon Glaxo and Eisai End Joint Development and Marketing Agreement for SN-308
Nippon Glaxo Ltd. [(Head office: Shibuya-ku, Tokyo, President: Hiroshi Konishi) hereafter referred to as Nippon Glaxo] and Eisai Co., Ltd. [(Head office: Bunkyo-ku, Tokyo, President: Haruo Naito) hereafter referred to as Eisai] announced today that they have agreed to terminate the co-development and co-marketing agreement of the treatment drug for migraine, SN-308 (Sumatriptan).
The decision to end the co-development and co-marketing agreement was made after Eisai reexamined its middle and long term corporate strategies and their decision was well received by Nippon Glaxo resulting in an amicable agreement to terminate the collaboration. Friendly relations will continue between the two companies.
Clinical developments of SN-308 in Japan consists of tablets, injections and nasal sprays. Eisai started participating in the clinical trials of tablets and injections at the late Phase II stage of development and Nippon Glaxo filed for their manufacturing approval in September 1993. Clinical trials of nasal sprays (SN-308I) was commenced by both companies in October 1994 and is presently in late Phase II.
Nippon Glaxo will continue to conduct future clinical trials and marketing is also planned to be conducted by Nippon Glaxo.
Sumatriptan is already marketed in approximately 70 countries worldwide for the treatment of migraine.
Corporate Communications Office
Public Relations Department